Management of Cushing’s Syndrome due to Ectopic Adrenocorticotropin Secretion with 1,Ortho-1, Para′-Dichloro-Diphenyl-Dichloro-Ethane: Findings in 23 Patients from a Single Center
The DOI matches its Crossref record; 7 of the 7 references it cites were found in a registry or an index.
Abstract
CONTEXT: Effective treatment for the ectopic ACTH secretion syndrome (EAS) remains a therapeutic challenge. Immediate curative surgery of the responsible nonpituitary tumor is often not possible. OBJECTIVE: The objective of the study was to evaluate 1,ortho-1, para'-dichloro-diphenyl-dichloro-ethane (O,p'DDD) therapy in EAS. DESIGN AND PATIENTS: Patients included 36 consecutive patients with EAS from a single center treated between 1990 and 2006. Twenty-three of these patients, including 18 women aged 53.7 +/- 12.9 yr (mean +/- sd), were treated with O,p'DDD. Patient follow-up was 8.04 +/- 9.6 yr. RESULTS: A mean daily O,p'DDD dose of 3.3 +/- 1.2 g Lysodren equivalent was given for a mean duration of 1.8 +/- 2.1 yr. Urinary cortisol decreased from 2603 +/- 3443 microg/d before treatment to 79 +/- 169 microg/d at the time of maximal O,p'DDD efficacy. Urinary cortisol was normalized in 21 of the 23 patients. Adrenal insufficiency was observed in 20 patients. This was associated with clinical improvement of Cushing's syndrome manifestations, including diabetes, hypertension, and hypokalemia. O,p'DDD plasma levels were 10.4 +/- 6.5 microg/ml in the 12 patients tested at the time of adrenal insufficiency. Side effects were observed during the first 6 months in seven of 15 patients (46%). National Cancer Institute-Classification Common Toxicity Criteria grade 1 or 2 digestive or neurologic toxicity resolved after withdrawal or reduction of O,p'DDD. Careful monitoring was essential to long-term control, clinical improvement, and good tolerability. Medical control of the disease allowed the subsequent characterization of tumors in eight of 13 patients with initially occult tumors. CONCLUSION: With close monitoring, O,p'DDD could be a potent medical treatment for long-term control and management of EAS.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Lacroix, A., Feelders, R. A., Stratakis, C. A., & Nieman, L. K. (2015) · The Lancet · doi:10.1016/s0140-6736(14)61375-1 · Cited by 1,777
Diagnosis and complications of Cushing’s syndrome: a consensus statement
Arnaldi, G., Angeli, A., Atkinson, A. B., Bertagna, X., Cavagnini, F., Chrousos, G. P., Fava, G. A., Findling, J. W., Gaillard, R. C., Grossman, A. B., et al. (2003) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2003-030871 · Cited by 1,362
Self-citationTreatment of adrenocorticotropin-dependent Cushing’s syndrome: a consensus statement
Biller, B. M. K., Grossman, A. B., Stewart, P. M., Melmed, S., Bertagna, X., Bertherat, J., Buchfelder, M., Colao, A., Hermus, A. R., Hofland, L. J., et al. (2008) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2007-2734 · Cited by 853
Self-citationClinical management of adrenocortical carcinoma
Fassnacht, M., & Allolio, B. (2009) · Best Practice & Research Clinical Endocrinology & Metabolism · doi:10.1016/j.beem.2008.10.008 · Cited by 349 · cited 1×
“It has been suggested in adrenocortical cancer treatment that O,p DDD plasma levels should be maintained within a narrow range (14–20 g/ml), both for its antitumor effects and to avoid serious side effects (41).”
BackgroundMidnight salivary cortisol for the initial diagnosis of Cushing's syndrome of various causes.
Yaneva, M., Mosnier-Pudar, H., Dugué, M.-A., Grabar, S., Fulla, Y., & Bertagna, X. (2004) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2003-031790 · Cited by 179
Self-citationNader, N., Raverot, G., Emptoz-Bonneton, A., Déchaud, H., Bonnay, M., Baudin, E., & Pugeat, M. (2006) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2005-2157 · Cited by 89 · cited 1×
“(40), thus increasing plasma levels of cortisol binding glob-”
BackgroundCarrasco, C. A., Coste, J., Guignat, L., Groussin, L., Dugué, M. A., Gaillard, S., Bertagna, X., & Bertherat, J. (2008) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2008-1171 · Cited by 83
Self-citation
Cited by
Efficiency and tolerance of mitotane in Cushing's disease in 76 patients from a single center
Baudry, C., Coste, J., Bou Khalil, R., Silvera, S., Guignat, L., Guibourdenche, J., Abbas, H., Legmann, P., Bertagna, X., & Bertherat, J. (2012) · European Journal of Endocrinology · doi:10.1530/eje-12-0358 · Cited by 187
Self-citationChortis, V., Taylor, A. E., Schneider, P., Tomlinson, J. W., Hughes, B. A., O'Neil, D. M., Libé, R., Allolio, B., Bertagna, X., Bertherat, J., et al. (2013) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2012-2851 · Cited by 154
Self-citationFleseriu, M., & Castinetti, F. (2016) · Pituitary · doi:10.1007/s11102-016-0742-1 · Cited by 87
Cardiovascular risk and mortality in patients with active and treated hypercortisolism
Li, D., El Kawkgi, O. M., Henriquez, A. F., & Bancos, I. (2020) · Gland Surgery · doi:10.21037/gs.2019.11.03 · Cited by 42
Syndromes de Cushing : physiopathologie, étiologie et principes thérapeutiques
Chabre, O. (2014) · La Presse Médicale · doi:10.1016/j.lpm.2014.02.001 · Cited by 21
Metadata
- Authors
- Donadille, B., Groussin, L., Waintrop, C., Abbas, H., Tenenbaum, F., Dugué, M.-A., Coste, J., Bertagna, X., & Bertherat, J.
- Venue
- The Journal of Clinical Endocrinology & Metabolism
- Publisher
- The Endocrine Society
- Published
- 2010-02-01
- Volume
- 95
- Issue
- 2
- Pages
- 537-544
- ISSN
- 0021-972X (ISSN-L)
- 1945-7197
- OpenAlex
- W2056643145
- Cited by
- 42
- References
- 7
- FWCI
- 2.42
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Management of Cushing’s Syndrome due to Ectopic Adrenocorticotropin Secretion with 1,Ortho-1, Para′-Dichloro-Diphenyl-Dichloro-Ethane: Findings in 23 Patients from a Single Center. https://app.cochat.ai/papers/10.1210/jc.2009-1317
- The paper
- Donadille, B., Groussin, L., Waintrop, C., Abbas, H., Tenenbaum, F., Dugué, M.-A., Coste, J., Bertagna, X., & Bertherat, J. (2010). Management of Cushing’s Syndrome due to Ectopic Adrenocorticotropin Secretion with 1,Ortho-1, Para′-Dichloro-Diphenyl-Dichloro-Ethane: Findings in 23 Patients from a Single Center. The Journal of Clinical Endocrinology & Metabolism. https://doi.org/10.1210/jc.2009-1317
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.